Navigation Links
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
Date:5/7/2008

NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.

A pre-recorded Webcast, with the lead tapentadol researchers, will be made available concurrent to the data presentations being made during the poster session at APS. Pre-registration is not required to view the webcast/podcast.

The presentation will provide an overview on tapentadol IR and review data from the following clinical posters:
-- Efficacy of Tapentadol Immediate Release in Patients With Pain After

Bunionectomy

-- Analgesic Efficacy of Tapentadol Immediate Release in Patients With

Pain From End-Stage Joint Disease

-- Tapentadol Immediate Release is Associated With Improved

Gastrointestinal Tolerability Compared With Oxycodone Immediate Release

Over 90 Days in Patients With Lower Back or Osteoarthritis Pain

The webcast/podcast and replay can be accessed by clicking on "Webcasts/Presentations" in the Investor Relations section of the Company's website at http://www.jnj.com.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Steroids Provide No Survival Benefit for Children With Bacterial Meningitis
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Gene Therapy Provides Vision to People who Were Nearly Blind
5. Arpida Provides Further Comments on the Pivotal Phase III Trials
6. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
9. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):